Study to Assess Change in Disease Activity and Adverse Events of RINVOQ in Adult Participants With Ankylosing Spondylitis in the Real-World Japan (SELECT AXIS RW)

Recruiting
All
Phase N/A
100 participants needed
12 Locations

Brief description of study

Axial spondyloarthritis (axSpA), which encompasses radiographic axSpA (r-axSpA, also known as ankylosing spondylitis [AS]) is an immune-mediated inflammatory disease primarily affecting the axial skeleton. This study will assess how effective Rinvoq is in treating axSpA.

Rinvoq is an approved drug for treating axSpA. Approximately 100 adult participants who are prescribed Rinvoq by their physician in accordance with local label will be enrolled in Japan.

Participants will receive Rinvoq as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 52 weeks.

There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Ankylosing Spondylitis
  • Gender: All

Inclusion Criteria:

  • Participant with clinical diagnosis of ankylosing spondylitis (AS) and meeting the modified New York Criteria for AS.
  • Participant who is administered the first dose of Rinvoq for AS.

Exclusion Criteria:

  • Participant with prior treatment by JAK inhibitors.
  • Participant currently participating in another clinical study except non-interventional study.
  • Participant for whom upadacitinib is contraindicated.
  • Participants who are not registered within 14 days after initiation of Rinvoq treatment for AS.

Updated on 08 Nov 2022. Study ID: P22-963

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Zip Code
Please provide your 5-digit zip code
0 0 /250
Other language

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team